Table 3 Characteristics of HSC grafts... | American Society of Hematology

Table 3

Characteristics of HSC grafts and outcome of HSCT

Patient no.	Donor source	HLA match	Composition of donor graft		Duration of ANC < 500/μL, d	Donor CD3⁺ cells, %*	Donor CD14⁺ cells, %*	Donor CD19⁺ cells, %*	Donor CD3⁻CD56⁺ cells, %*	Infections	GVHD†	Outcome/follow-up, mo
Patient no.	Donor source	HLA match	CD34⁺, ×10⁶/kg	CD3⁺, ×10⁶/kg	Duration of ANC < 500/μL, d	Donor CD3⁺ cells, %*	Donor CD14⁺ cells, %*	Donor CD19⁺ cells, %*	Donor CD3⁻CD56⁺ cells, %*	Infections	GVHD†	Outcome/follow-up, mo
1	MRD	10/10	7.0	247	0	87	99	100	100	CRBI	Skin/liver	Alive/25
2	MRD	10/10	4.1	380	11	99	100	100	100	IFI, CMV viremia, BSI	Skin/liver	Died/3
3	MUD	8/8	6.87	354	10	99	100	100	100		NO	Alive/23
4	MUD	10/10	8.25	207	10	79	100	100	99		Skin	Alive/11
5	UCB	4/6	0.787	3.48	76	100	100	100	100	BK viremia, CRBI, IFI, cellulitis, CMV viremia	NO	Alive/18
6	Double				14					FN, HZ, endocarditis	Skin/GI	Alive/10
	UCB 1	4/6	0.186	5.04		16	0	0	30
	UCB 2	4/6	0.658	10.5		77	100	100	70

Patient no.	Donor source	HLA match	Composition of donor graft		Duration of ANC < 500/μL, d	Donor CD3⁺ cells, %*	Donor CD14⁺ cells, %*	Donor CD19⁺ cells, %*	Donor CD3⁻CD56⁺ cells, %*	Infections	GVHD†	Outcome/follow-up, mo
Patient no.	Donor source	HLA match	CD34⁺, ×10⁶/kg	CD3⁺, ×10⁶/kg	Duration of ANC < 500/μL, d	Donor CD3⁺ cells, %*	Donor CD14⁺ cells, %*	Donor CD19⁺ cells, %*	Donor CD3⁻CD56⁺ cells, %*	Infections	GVHD†	Outcome/follow-up, mo
1	MRD	10/10	7.0	247	0	87	99	100	100	CRBI	Skin/liver	Alive/25
2	MRD	10/10	4.1	380	11	99	100	100	100	IFI, CMV viremia, BSI	Skin/liver	Died/3
3	MUD	8/8	6.87	354	10	99	100	100	100		NO	Alive/23
4	MUD	10/10	8.25	207	10	79	100	100	99		Skin	Alive/11
5	UCB	4/6	0.787	3.48	76	100	100	100	100	BK viremia, CRBI, IFI, cellulitis, CMV viremia	NO	Alive/18
6	Double				14					FN, HZ, endocarditis	Skin/GI	Alive/10
	UCB 1	4/6	0.186	5.04		16	0	0	30
	UCB 2	4/6	0.658	10.5		77	100	100	70

ANC indicates absolute neutrophil count; UCB, umbilical CB; MRD, matched related donor; MUD, matched unrelated donor; CRBI, catheter-related blood stream infection; IFI, invasive fungal infection; BSI, blood stream infection; BK, BK virus; FN, fever and neutropenia; HZ, herpes zoster; and GI, gastrointestinal.

The percentage of donor cells at last follow-up.

†

Patients 1, 4, and 6 had late acute grade I-II GVHD at 8, 10, and 6 months after transplantation, respectively. All responsive to steroids, now resolved. Patient 2 developed steroid refractory acute GVHD. There were no instances of chronic GVHD.

View Large

This Feature Is Available To Subscribers Only